Cytoskeletal proteins as glioblastoma biomarkers and targets for therapy

ǂa ǂsystematic review

Alja Zottel (Author), Ivana Jovchevska (Author), Neja Zupanec (Author), Radovan Komel (Author)

Abstract

Glioblastoma, the most common primary brain malignancy, is an exceptionally fatal cancer. Lack of suitable biomarkers and efficient treatment largely contribute to the therapy failure. Cytoskeletal proteins are crucial proteins in glioblastoma pathogenesis and can potentially serve as biomarkers and therapeutic targets. Among them, GFAP, has gained most attention as potential diagnostic biomarker, while vimentin and microtubules are considered as prospective therapeutic targets. Microtubules represent one of the best anti-cancer targets due to their critical role in cell proliferation. Despite testing in clinical trials, the efficiency of taxanes, epothilones, vinca-domain binding drugs, colchicine-domain binding drugs and %-tubulin binding drugs remains to be confirmed. Moreover, tumor treating field that disrupts microtubules draw attention because of its high efficiency and is called "the fourth cancer treatment modality". Thereby, because of the involvement of cytoskeleton in key physiological and pathological processes, its therapeutic potential in glioblastoma is currently extensively investigated.

Keywords

citoskelet;glioblastom;označevalci;cytoskeleton;glioblastoma;biomarkers;

Data

Language:	English
Year of publishing:	2021
Typology:	1.02 - Review Article
Organization:	UL MF - Faculty of Medicine
UDC:	616-006
COBISS:	54458627
ISSN:	1879-0461
Views:	102
Downloads:	30
Average score:	0 (0 votes)
Metadata:

Other data

Secondary language:	Slovenian
Secondary keywords:	citoskelet;glioblastom;označevalci;
Type (COBISS):	Article
Pages:	str. 1-13
Issue:	ǂVol. ǂ160
Chronology:	2021
DOI:	10.1016/j.critrevonc.2021.103283
ID:	16129085